Five things for pharma marketers to know: Friday, May 27, 2016

Five things for pharma marketers to know: Friday, May 27, 2016

Baby powder lawsuit impacts J&J's reputation; new bacterial infection raises concern about treatment options; Valeant reportedly rejected offer from Takeda

AstraZeneca pulls Take it From a Fish campaign

AstraZeneca pulls Take it From a Fish campaign

The unbranded campaign won the top prize at the 2015 Lions Health festival in Cannes.

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

The Science and Psychology behind Patient Engagement

The Science and Psychology behind Patient Engagement

Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?

The commercial carousel continues to spin: Gilead's head of commercial departs

The commercial carousel continues to spin: Gilead's head of commercial departs

Gilead announced that its head of commercial operations left the company.

Conflicting polls highlight uncertainty about the public's opinion of pharma

Conflicting polls highlight uncertainty about the public's opinion of pharma

Two recent polls paint a complicated picture of the public's opinion of the pharma industry.

Five things for pharma marketers to know: Wednesday, May 25, 2016

Five things for pharma marketers to know: Wednesday, May 25, 2016

Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller

Healthcare Content Marketing Still Lags But Can Fill Pharma Marketing Voids

Healthcare Content Marketing Still Lags But Can Fill Pharma Marketing Voids

Such intense interest in health content is a rich opportunity to engage, inform, support, and motivate key customer constituencies.

Five things for pharma marketers to know: Tuesday, May 24, 2016

Five things for pharma marketers to know: Tuesday, May 24, 2016

The FDA accepts Samsung's biosimilar for review; Sanofi retools executive committee; Entresto may get a boost from updated care guidelines

Practice Fusion founder launches heart-monitoring wearable

Practice Fusion founder launches heart-monitoring wearable

The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.

Pfizer's smoking-cessation app came from internal competition

Pfizer's smoking-cessation app came from internal competition

Pfizer brand teams competed in a shark-tank style challenge, with the winning teams receiving funding for their ideas.

J&J taps Sneed as communications chief

J&J taps Sneed as communications chief

Johnson & Johnson has appointed Michael Sneed, its worldwide VP of global corporate affairs, to the additional role of chief communications officer.

Five things for pharma marketers to know: Monday, May 23, 2016

Five things for pharma marketers to know: Monday, May 23, 2016

E.U. lifts warning on Pfizer's Chantix; Obama's Medicare Part B proposal panned by lawmakers; France to propose stricter rules for clinical trials

W2O sells stake to private-equity firm

W2O sells stake to private-equity firm

The agency network said the private equity firm won't be involved in its day-to-day operations, but it will help its growth strategy.

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Blue Cross Blue Shield RI on introducing email segmentation

Blue Cross Blue Shield RI on introducing email segmentation

Health insurance provider Blue Cross Blue Shield Rhode Island drove engagement, leads, and conversion through its segmented campaigns.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Industry criticizes FDA's proposed DTC studies

Industry criticizes FDA's proposed DTC studies

Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

The Medicines Company appoints former Biogen exec to lead commercial activities

The Medicines Company appoints former Biogen exec to lead commercial activities

Tony Kingsley will oversee the company's daily operations and commercial activities.

Novartis splits pharma division, shakes up management team

Novartis splits pharma division, shakes up management team

Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.

Ponemon: Cybercrime is top cause for healthcare data breaches

Ponemon: Cybercrime is top cause for healthcare data breaches

A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.

Five things for pharma marketers to know: Tuesday, May 17, 2016

Five things for pharma marketers to know: Tuesday, May 17, 2016

Online doctors prescribe drugs without adequate warnings; House lawmakers to discuss Part B proposal; obesity drugs struggle for market share

Valeant offers discounts for high-priced heart drugs

Valeant offers discounts for high-priced heart drugs

The drugmaker said its rebate program will discount Nitropress and Isuprel, following a year of relentless criticism about the prices of the therapies.

Omnicom PR Group acquires healthcare shop Rabin Martin

Omnicom PR Group acquires healthcare shop Rabin Martin

It is the group's first acquisition since it was assembled in February under CEO Karen van Bergen.

Five things for pharma marketers to know: Monday, May 16, 2016

Five things for pharma marketers to know: Monday, May 16, 2016

Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill

U by Kotex opens up a period-themed pop-up shop

U by Kotex opens up a period-themed pop-up shop

"The Period Shop" is the first effort in a multi-year "Period Projects" campaign.

Novartis considers new sales model for experimental cancer therapy

Novartis considers new sales model for experimental cancer therapy

Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.

The Marketer's Role is To Be the Voice of the Patient

The Marketer's Role is To Be the Voice of the Patient

Maybe we have just forgotten the true reason why marketing exists in organizations.

Five things for pharma marketers to know: Friday, May 13, 2016

Five things for pharma marketers to know: Friday, May 13, 2016

HCV market share battle is still underway; Regeneron CEO blasts criticism of Praluent's price; ProPublica database used to find docs to prescribe painkillers

Lobbyists argue DTC ad tax deduction may be a casualty of reform

Lobbyists argue DTC ad tax deduction may be a casualty of reform

Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.

Five things for pharma marketers to know: Thursday, May 12, 2016

Five things for pharma marketers to know: Thursday, May 12, 2016

Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart

Greyhealth CEO: Women, millennials are healthcare's change agents

Greyhealth CEO: Women, millennials are healthcare's change agents

Healthcare communicators are confronting a rapidly changing market due to how consumers, providers, and platforms are changing.

Q&A: Toby Cosgrove on running the Cleveland Clinic and community comms

Q&A: Toby Cosgrove on running the Cleveland Clinic and community comms

The Cleveland Clinic's CEO discusses how he keeps the hospital on top of its game and educates the community it serves.

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

Five things for pharma marketers to know: Tuesday, May 10, 2016

Five things for pharma marketers to know: Tuesday, May 10, 2016

U.S. investors want lobbyists to make a better case on drug pricing; pancreatic vaccine failed in Phase-III trial; Epirus cuts 40% of its workforce

Five things for pharma marketers to know: Monday, May 9, 2016

Five things for pharma marketers to know: Monday, May 9, 2016

GSK is not considering a breakup; Merck CEO wants to make a deal; Gates Foundation offers grant for polio vaccine

Five things for pharma marketers to know: Friday, May 6, 2016

Five things for pharma marketers to know: Friday, May 6, 2016

Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee

An emotional bond with patients is key, says Elemental Machines' Iyengar

An emotional bond with patients is key, says Elemental Machines' Iyengar

At the MM&M Transforming Healthcare conference, Iyengar told attendees how to take into account a consumer's behavior and emotion when marketing medical products.

Care Angel wins MM&M Shark Tank challenge 2016

Care Angel wins MM&M Shark Tank challenge 2016

The Siri for Seniors took the top prize at the second MM&M Shark Tank for its annual healthcare conference.

Omnicom to acquire BioPharm Communications

Omnicom to acquire BioPharm Communications

Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.

Five things for pharma marketers to know: Thursday, May 5, 2016

Five things for pharma marketers to know: Thursday, May 5, 2016

U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers

Time is running out: Fill in MM&M's Agency questionnaire

Time is running out: Fill in MM&M's Agency questionnaire

Did your agency report record growth in 2015? Tell us why when you fill out the A-to-Z questionnaire for MM&M's upcoming agency issue. The deadline is Friday.

Five things for pharma marketers to know: Wednesday, May 4, 2016

Five things for pharma marketers to know: Wednesday, May 4, 2016

The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign

Five things for pharma marketers to know: Tuesday, May 3, 2016

Five things for pharma marketers to know: Tuesday, May 3, 2016

IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service

Five things for pharma marketers to know: Monday, May 2, 2016

Five things for pharma marketers to know: Monday, May 2, 2016

Express Scripts to roll out pricing response program; the FDA approves new Parkinson's disease treatment; Regeneron's plaque psoriasis drug hits endpoint

Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.

Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare Communications Group has hired Kipp Jarecke-Cheng as global chief communications officer.

Five things for pharma marketers to know: Wednesday, April 27, 2016

Five things for pharma marketers to know: Wednesday, April 27, 2016

Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula

Following positive outcomes data, a new diabetes class is on the rise

Following positive outcomes data, a new diabetes class is on the rise

Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.

Five things for pharma marketers to know: Tuesday, April 26, 2016

Five things for pharma marketers to know: Tuesday, April 26, 2016

FDA panel says Duchenne drug is not effective; Bill Ackman to appear before Senate committee investigating pricing issues; Daiichi Sankyo to open new headquarters

About.com launches first standalone health site Verywell

About.com launches first standalone health site Verywell

Verywell.com presents physician-reviewed health and wellness content that aims to be "gentler" than other health websites.

Biogen under investigation for patient-assistance programs

Biogen under investigation for patient-assistance programs

The drugmaker disclosed in its first-quarter earnings report that it is being investigated over ties to nonprofit foundations.

FCB agency veteran, Renée Wills, joins Kinch

FCB agency veteran, Renée Wills, joins Kinch

After six years as president of Trio, Renée Wills has joined newly formed agency Kinch.

Five things for pharma marketers to know: Monday, April 25, 2016

Five things for pharma marketers to know: Monday, April 25, 2016

Valeant names new CEO; Novartis weighs sales of stake in Roche; FDA ad panel to recommend DMD drug

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

Five things for pharma marketers to know: Friday, April 22, 2016

Five things for pharma marketers to know: Friday, April 22, 2016

AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen CEO George Scangos told investors that the company's DTC campaign for Tecfidera was designed to address low awareness for the drug.

Five things for pharma marketers to know: Thursday, April 21, 2016

Five things for pharma marketers to know: Thursday, April 21, 2016

Allergan plans sales blitz for Kybella; Novartis U.S. lead steps down; analysts say PCSK9 sales are disappointing so far

An explainer: some of IBM Watson Health's key partnerships

An explainer: some of IBM Watson Health's key partnerships

IBM Watson Health has publicly announced deals with 18 different companies and patient organizations over the past few years.

Brazilian agencies create billboard that kills Zika-carrying mosquitoes

Brazilian agencies create billboard that kills Zika-carrying mosquitoes

The billboards themselves operate on simple principles: fool mosquitoes into thinking they've found a human, and then trap them until they die of dehydration.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Watson Health partners with drug and devicemakers to tap into real-world data

Watson Health partners with drug and devicemakers to tap into real-world data

Industry is partnering with Watson to try and solve some of healthcare's most pressing questions.

Competition drives down sales of J&J's Olysio

Competition drives down sales of J&J's Olysio

The company said growth in its immunology portfolio offset declining Olysio sales.

Five things for pharma marketers to know: Tuesday, April 19, 2016

Five things for pharma marketers to know: Tuesday, April 19, 2016

Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class

Is virtual reality the ultimate emotive storytelling tool?

Is virtual reality the ultimate emotive storytelling tool?

Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.

How Watson for Oncology is advancing cancer care

How Watson for Oncology is advancing cancer care

IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.

Bayer creates new role: VP of comms for consumer health

Bayer creates new role: VP of comms for consumer health

He plans to expand the company's consumer health marketing.

Five things for pharma marketers to know: Monday, April 18, 2016

Five things for pharma marketers to know: Monday, April 18, 2016

Valeant mulls over fire sale; research shows that Opdivo helps advanced melanoma patients survive longer; AstraZeneca considers Medivation

Challenges exist, even as excitement grows for big data market

Challenges exist, even as excitement grows for big data market

The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.

What is cognitive computing, and what does it look like in healthcare?

What is cognitive computing, and what does it look like in healthcare?

Already, there's cognitive cooking for your kitchen and cognitive coaching for your daily run. What's Watson's vision for medicine?

A look at Watson Health in New York

A look at Watson Health in New York

The editorial staff of MM&M recently visited IBM Watson's offices in New York. What ensued was the creation of Watson Week.

Five things for pharma marketers to know: Friday, April 15, 2016

Five things for pharma marketers to know: Friday, April 15, 2016

Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs

MM&M's Agency questionnaire is now available

MM&M's Agency questionnaire is now available

The questionnaire gives agencies the opportunity to contribute information to MM&M's definitive Agency A-to-Z directory, which will be published in the July issue.

Five things for pharma marketers to know: Thursday, April 14, 2016

Five things for pharma marketers to know: Thursday, April 14, 2016

Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license

Second-generation IBM star pushes for partnerships

Second-generation IBM star pushes for partnerships

With a lead role in IBM Watson's bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise's most important individuals.

U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Wednesday, April 13, 2016

Five things for pharma marketers to know: Wednesday, April 13, 2016

Sanofi is reportedly interested in buying Medivation; Sean Parker funds $250 million cancer research institute; FDA will review Merck's allergy biologic

Creative partners should push pharma clients to tell better stories

Creative partners should push pharma clients to tell better stories

Industry criticism can create opportunities for drugmakers and other healthcare organizations to create a stronger narrative.

FDA committee votes no on Clovis lung-cancer drug

FDA committee votes no on Clovis lung-cancer drug

The FDA advisory committee voted 12-1 against approving the therapy, citing safety issues and requesting more data.

Five things for pharma marketers to know: Tuesday, April 12, 2016

Five things for pharma marketers to know: Tuesday, April 12, 2016

California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use

The FDA approves AbbVie's and Roche's blood cancer drug

The FDA approves AbbVie's and Roche's blood cancer drug

Analysts have estimated the drug could reach $2 billion in sales in the next four years.

Five things for pharma marketers to know: Monday, April 11, 2016

Five things for pharma marketers to know: Monday, April 11, 2016

Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Five things for pharma marketers to know: Thursday, April 7, 2016

Five things for pharma marketers to know: Thursday, April 7, 2016

Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's

Omnicom merges Corbett, LLNS into TBWA/ WorldHealth brand

Omnicom merges Corbett, LLNS into TBWA/ WorldHealth brand

LLNS CEO Sharon Callahan has been named CEO of TBWA/WorldHealth, which is based in New York.

InVentiv Health files for IPO

InVentiv Health files for IPO

It operates a number of ad agencies, like GSW and Palio, as well as a group of PR firms that includes Chandler Chicco Agency.

Drugmakers go to DTC to promote IBS drugs

Drugmakers go to DTC to promote IBS drugs

The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

New mobile app seeks to address medication adherence

New mobile app seeks to address medication adherence

CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Tuesday, April 5, 2016

Five things for pharma marketers to know: Tuesday, April 5, 2016

Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.

Five things for pharma marketers to know: Monday, April 4, 2016

Five things for pharma marketers to know: Monday, April 4, 2016

Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data

The FDA issues warning letter to Shionogi over co-pay voucher

The FDA issues warning letter to Shionogi over co-pay voucher

The drugmaker marketed a co-pay assistance voucher that failed to provide any risk information about its drug Ulesfia.

OPINION

Email Newsletters